
Valeritas
Founded Year
2006Stage
Acquired | AcquiredTotal Raised
$281.59MValuation
$0000About Valeritas
Valeritas is committed to developing and commercializing treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas' portfolio is headlined by the V-Go disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy. In addition to the V-Go, Valeritas' delivery technology portfolio includes the h-Patch for the delivery of other compounds beyond insulin, the Mini-Ject Pre-Filled Needle-Free Delivery System, and the Micro-Trans Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide products that allow precise dosing in previously difficult to treat conditions. On February 10th, 2020, Valeritas was acquired by Zealand million.
Loading...
Loading...
Valeritas Patents
Valeritas has filed 58 patents.
The 3 most popular patent topics include:
- fluid dynamics
- drug delivery devices
- dosage forms

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/13/2018 | 8/8/2023 | Medical equipment, Drug delivery devices, Dosage forms, Copolymers, Biodegradable plastics | Grant |
Application Date | 7/13/2018 |
---|---|
Grant Date | 8/8/2023 |
Title | |
Related Topics | Medical equipment, Drug delivery devices, Dosage forms, Copolymers, Biodegradable plastics |
Status | Grant |
Latest Valeritas News
Jun 20, 2023
| By Valeritas, Insulet, Animas, Medtronic, CeQur The market for Disposable Insulin-Delivery Devices is anticipated to be worth US$ 14,585.6 million in 2022, with a compound yearly growth rate (CAGR) of 7.7% between 2022 and 2032, for a total market value of US$ 32,887.5 million. This growth is being driven mostly by a rise in diabetes-related health spending in emerging countries. According to the International Diabetes Federation (IDF), one-tenth of all diabetics have Type 1, and 10% do not currently use insulin delivery devices, implying that the Disposable Insulin-Delivery Device market has significant growth potential during the forecast period. A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-5059 In comparison to syringes, pumps, and jet injectors, pens are the most common insulin delivery technique, accounting for more than 36% of the market. The design and convenience of use of pens have led to their popularity. NovoPen is now the market leader, and it includes a memory function as an added feature. Home care is the primary end-user of Disposable Insulin-Delivery Devices, accounting for more than 45% of the market. The cost-effectiveness of home care versus hospital treatment contributes significantly to this trend. Furthermore, the portability of these devices increases their utility for home care applications. Future industry Insights did an in-depth analysis of the Disposable Insulin-Delivery Device industry, encompassing both micro and macro variables, in their latest market study titled ‘Disposable Insulin-Delivery Device Market.’ Key Takeaways from Disposable Insulin-Delivery Device Market North America controls 33% of the market. Rising diabetes incidence, legitimate government schemes, and the advent of numerous disposable insulin delivery device manufacturers could all play a role. According to the CDC, diabetes affects more than 37 million individuals in the United States. Because to advancements in healthcare infrastructure across Europe, Europe now controls 29% of the market. In 2019, over 32 million people in the EU were diagnosed with diabetes. Rising diabetes awareness is one of the primary reasons driving the Asia-Pacific Disposable Insulin-Delivery Device market, and this trend is projected to continue. Last few days to get reports at discounted prices, offer expires soon! Competitive Landscape In February 2022, Abbott announced a partnership with Fitterfly, Healthifyme, Zyla Health, 1MG, GOQii, PharmEasy, Sugar.fit, and BeatO as a step towards holistic diabetes control treatment. Abbott provides glucose monitoring solutions to over 8 million diabetes patients through collaborations, with 6.5 million having access to 1MG and PharmEasy. Insulet Corp. announced in January 2022 that the new Omnipod 5 system had been approved by the US FDA, introducing it into the field of AID (automated insulin delivery). In March 2022, Novo Nordisk announced the availability of two smart linked insulin pens called ‘NovoPen Echo Plus’ and ‘NovoPen 6’ for patients receiving Novo Nordisk insulin in the UK. Sanofi and Roche will collaborate in November 2021 to increase the usage of disposable insulin pens. Local players are also being approached in order to expand market penetration. “A large chunk of population is contracting diabetes, which asks for Disposable Insulin-Delivery Devices”, thereby accelerating the market for the same”, says an analyst from Future Market Insights. Want more insights: In North America, the market is mature and dominated by established players such as Novo Nordisk and Eli Lilly. The increasing prevalence of diabetes, favorable reimbursement policies, and the availability of advanced insulin delivery technologies have been the key drivers of market growth in this region. We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5059 Key Segments Profiled in the Disposable Insulin-Delivery Device Market Disposable Insulin-Delivery Device Market by Product Type: Disposable Insulin-Delivery Pumps Disposable Insulin-Delivery Devices for Type I Diabetes Disposable Insulin-Delivery Devices for Type II Diabetes Disposable Insulin-Delivery Device Market by Distribution Channel: Disposable Insulin-Delivery Devices Sales via Hospital Pharmacies Disposable Insulin-Delivery Devices Sales via Retail Pharmacies Disposable Insulin-Delivery Devices Sales via Online Sales Disposable Insulin-Delivery Devices Sales via Diabetes Clinics About Future Market Insights, Inc. Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years. Contact:
Valeritas Frequently Asked Questions (FAQ)
When was Valeritas founded?
Valeritas was founded in 2006.
Where is Valeritas's headquarters?
Valeritas's headquarters is located at 750 Route 202 South, Bridgewater.
What is Valeritas's latest funding round?
Valeritas's latest funding round is Acquired.
How much did Valeritas raise?
Valeritas raised a total of $281.59M.
Who are the investors of Valeritas?
Investors of Valeritas include Zealand Pharma, Valeritas, MPM Capital, Pitango Venture Capital, Welsh Carson Anderson & Stowe and 12 more.
Who are Valeritas's competitors?
Competitors of Valeritas include PharmaJet, Phreesia, HUTCHMED, Pantec Biosolutions, Replenish and 7 more.
Loading...
Compare Valeritas to Competitors
UMD aims to develop drug delivery technologies and products, with a focus on women's health.
The Liposome Company is developing liposome-based drug delivery
Depotech is developing methods for drug delivery
Cytogel, Inc., is working on the development of promising drug candidates and drug delivery technologies
Replenish is a company focused on the development of medical devices, specifically within the pharmaceutical and healthcare industry. Their main product is a small, implantable, refillable drug pump designed to periodically inject medication for patients suffering from age-related macular degeneration. The company primarily serves the healthcare sector, with a particular focus on retinal therapeutics. It was founded in 2007 and is based in Pasadena, California.
Medlogics is an early stage medical device company developing a broad platform technology for drug delivery. The initial focus is product development of polymer-free stent drug delivery.
Loading...